A 2025 preclinical bioRxiv preprint reported that low-dose semaglutide produced cardiac and hepatic benefits independent of weight loss in obese rats with HFpEF, but this is animal data and has not been replicated in humans (bioRxiv preprint, 2025)
Altmed is built for people who want practical answers without being bounced between disconnected offices
These assessments reveal patterns that inform whether your body is in a phase of active inflammation requiring additional support, or whether its ready to respond optimally to peptide-assisted recovery
In the event that impacted product is administered to a patient, there is an increased risk that severe adverse events such as invasive bacterial infection, including bacterial meningitis, septicemia, and limited adverse events such as fever, chills, malaise, and cutaneous abscess may occur
#RB042 #ClinicalTrial #FirstInHuman #COPD #SSOtherapeutics #SSO #Oligonucleotides #RestoreTheBalance To view or add a comment, sign in A growing concern in the peptide space is not the compounds themselvesbut how they are being used
